Seeking Alpha

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia - Slideshow

The following slide deck was published by Crinetics Pharmaceuticals, Inc. in conjunction with this event.
Seeking Alpha

Crinetics Pharmaceuticals, Inc. (CRNX) Discusses PALSONIFY Launch Progress and Phase 2 Atumelnant Results in Congenital Adrenal Hyperplasia Transcript

Welcome to the Crinetics Pharmaceuticals Corporate Update Conference Call. [Operator Instructions] I will now turn the call over to Gayathri Diwakar, Head of Investor Relations. Please go ahead. Thank ...
Yahoo Finance

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of ...

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced PALSONIFY U.S. unaudited and preliminary net product revenue of over $5 million for ...
BioSpace

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs.
BioSpace

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of ...

Strong PALSONIFY U.S. Launch Execution Resulted in Unaudited and Preliminary Net Product Revenue of >$5 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Atumelnant ...
Business Insider

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 ...